Category: Dyslipidemia
-
-
-
-
-
-
-
-
-
-
-
Save The Date: Hypertension and Hyperlipidemia Academy, No. 16
May 7, 2024Save The Date: 15th H&H Academy
-
ACC.24 Congress Coverage: Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl
April 27, 2024ACC.24: REDUCE-IT trial
-
ACC.24 Congress Coverage: An “Inclisiran First” Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease
April 27, 2024ACC.24: VICTORION-INITIATE trial
-
ACC.24 Congress Coverage: A Technology-Assisted Web Application for Consumer Access to a Nonprescription Statin Medication
April 22, 2024ACC.24: TACTiC Trial
-
ACC.24 Congress Coverage: Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction
April 17, 2024Infarction ACC.24: AEGIS-II Trial
-
ACC.24 Congress Coverage: Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
April 17, 2024ACC.24: Bridge TIMI 73a Trial
-
-
-
-
Diabeat, 9th session: is Metformin still the champion for T2D and heart disease? a debate: Pros by Dr. Hadaegh
January 6, 2024Diabeat 9th session, case based discussion
-
Diabeat, 9th session: is Metformin still the champion for T2D and heart disease? a debate: Cons by Dr. Ghanavati
January 6, 2024Diabeat 9th session, case based discussion
-
Diabeat: the 9th diabetes masterclass for cardiologists, case-based discussion
December 30, 2023Diabeat 9th session, case based discussion
-
-
-
-
AHA23 Congress Coverage: Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial
November 20, 2023A23 Congress Coverage: Lepodisiran Dose-Ascending Trial
-
AHA23 Congress Coverage: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes: SELECT trial
November 18, 2023AHA23 Congress Coverage: Semaglutide in obesity and no DM (SELECT trial)
-
-
-
-
ESC 2023 Congress Coverage: 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
September 17, 2023ESC 2023: New DM and CVD Guideline
-
-
-
Impact: Combination lipid-lowering therapy after PCI
August 1, 2023Impact: Dyslipidemia treatment after PCI
-
-
Vision: Adults with fasting TG=150-500mg with ASCVD or DM
July 3, 2023Vision: Mild hypertriglyceridemia in moderate to high risk patients
-
-
-
Hypertension and Hyperlipidemia Academy: clinical tips for nurses and non-physician healthcare professionals
May 18, 2023H&H Academy: clinical tips for non-physicians
-
-
Young Cardiologist Award 1402 Introduction video by Dr. Aminian
May 18, 2023YCA 1402 introduction by Dr. Aminian
-
-
Young Cardiologist Award 1402 Introduction video by Dr. Shishehbor
May 13, 2023YCA 1402 introduction by Dr. Shishehbor
-
-
-
Save the Date: American College of Cardiology 2023 Congress Coverage
May 1, 2023Save the Date: ACC.23 congress coverage
-
-
Young Cardiologist Award 1402 Introduction video by A. Yahyavi, MD
April 29, 2023YCA 1402 introduction by Dr. Yahyavi
-
-
Vision: Adults with fasting TG=150-500mg without ACVD or DM
April 15, 2023Vision: Mild hypertriglyceridemia in low-risk patients
-
Daily Cardiology Symposium 1402 Save The Date poster Motion
April 10, 2023DCS 1402 Save The Date Poster Motion
-
-
-
-
-
Hypertension and Hyperlipidemia Academy: Smoothing the path to cardiovascular risk reduction
February 15, 2023H&H Academy: CVD risk reduction
-
-
Impact: Effect of statin therapy on muscle symptoms
September 26, 2022Impact: Effect of statin therapy on muscle symptoms
-
-
-
-
Save the date: European Society of Cardiology 2022 congress coverage
August 22, 2022Save the date: ESC 2022 congress coverage
-
Save the date: Hypertension and Hyperlipidemia Academy No. 10
August 18, 2022Save the date: H&H Academy No. 10
-
-
Hypertension and Hyperlipidemia Academy, 10: for non-physician healthcare profesionals
July 19, 2022H&H Academy 10, for non-physician healthcare professionals
-
-
-
-
Daily Cardiology Symposium 1401, Day 1 Panel 1: Pharmacotherapy in CAD
June 26, 2022DCS 1401: Pharmacotherapy in CAD
-
-
-
-
-
Daily Cardiology Symposium 1401 faculty and executive committee motion
May 14, 2022DCS 1401 faculty and executive committee motion
-
Save the date: Hypertension and Hyperlipidemia Academy, 8th
May 10, 2022Save the date: 8th H&H Academy
-
-
American College of Cardiology (ACC) congress 2022 landmark trials review
May 3, 2022ACC 2022 congress coverage
-
Daily Cardiology Symposium 1401 faculty and executive committee
April 18, 2022DCS 1401 faculty and executive committee
-
-
-
-
Familial hypercholesterolemia, a narrative review, part 2: diagnosis and screening
March 11, 2022FH 1: diagnosis and screening
-
-
-
Save the date: Hypertension and Hyperlipidemia Academy 7
March 3, 2022Save the date: the 7th H&H Academy session
-
-
-
-
-
-
Familial hypercholesterolemia, a narrative review, part 1: definition and burden
January 14, 2022FH 1: Definition and burden
-
Hypertension and Hyperlipidemia Academy 5, a hybrid event
January 7, 20225th session of H&H Academy, online and onsite
-
Save the date: A glimpse of DCS 1400 and invitation to DCS 1401
January 7, 2022DCS 1400 review and what’s coming next
-
-
-
-
Cardiometabolic Grand round, Session 5
November 21, 2021The 5th session of Cardiometabolic grand round
-
Save the date: Hypertension and hyperlipidemia academy, session 4
November 16, 2021The 4th session of Hypertension and hyperlipidemia academy
-
Save the date: Umbrella: Heart and Stroke
November 14, 2021The second program of Umbrella series: Heart and Stroke
-
Save the date: Cardiometabolic grand round, 5th session
November 8, 2021The 5th session of Cardiometabolic grand round program
-
Primary prevention in dyslipidemia as the only cardiovascular risk factor
November 4, 2021Dyslipidemia in primary prevention of low-risk patients
-
Late-breaking Science in Cardiovascular disease prevention
November 2, 2021ESC 2021 cardiovascular prevention guideline lectures and discussion
-
Save the date: Cardiorenal Metabolic Crossroads: Case-based Panel Discussion, 4th Session
November 1, 2021The 4th session of Cardiorenal metabolic crossroads program
-
Management of dyslipidemia in diabetic patients
October 24, 2021DLP and T2DM: approach and management
-
DiaBeat: The Beating Heart of Diabetes (8th session)
October 19, 20218th Diabetes Masterclass for Cardiologists
-
Save the date: Late-breaking Science in Cardiovascular disease prevention
October 19, 2021ESC 2021 cardiovascular prevention guideline lectures and discussion
-
-
-
The clinical landscape for Diabetes and Cardiovascular disease
August 24, 2021T2DM and cardiovascular diseases: The clinical landscape
-
-
DiaBeat: The Beating Heart of Diabetes (7th session), a scientific debate
August 14, 20217th Diabetes Masterclass for Cardiologists
-
From optimal medical therapy to revascularization in CCS
August 14, 2021Choosing the best therapeutic strategy in CCS
-
Save the date: The first Umbrella event: chronic coronary syndrome
August 8, 2021First Umbrella session: CCS
-
-
-
Save the date: Umbrella, Focused cardiology forums
July 27, 2021The first session of Umbrella series
-
Marking the antiplatelet therapy maze in ACS
July 12, 2021How to prevent atherosclerotic cardiovascular events
-
DiaBeat: The Beating Heart of Diabetes (6th session)
June 24, 20216th Diabetes Masterclass for Cardiologists
-
Cardiometabolic Grand Round: 4th session
June 24, 2021Guideline-directed cardiovascular evaluations before surgery
-
DCS 1400: session 1, HTN and DLP
June 16, 2021The first panel of DCS 1400: hypertension and dyslipidemia
-
-
Save the date: Cardiometabolic Grand Round 4th session
June 1, 2021The fourth session of Cardiometabolic grand round
-
How to reduce the atherosclerotic cardiovascular risk
May 18, 2021A case-based Review on HTN and DLP management
-
Updates on the management of Diabetes and cardiometabolic disease
May 18, 2021Actoverco Diabetes Lunch Webinar
-
DiaBeat: The Beating Heart of Diabetes (5th session)
May 1, 20215th Diabetes Masterclass for Cardiologists
-
Save the date: Abidi Hypertension and Hyperlipidemia Academy
April 19, 2021Keeping up-to-date on HTN and DLP treatment
-
Daily Cardiology Symposium 1400. Concise, Precise, Practical
April 10, 2021Case-based review of common cardiovascular practice The digital experience
-
PCSK9 inhibitors place in patients with cardiometabolic diseases
March 16, 2021PCSK9 inhibitors from two perspectives of Endocrinologist & Cardiologist
-
Save the date: Daily Cardiology Symposium 1400
March 11, 2021Case-based review of common cardiovascular practice
-
-
Save the date: 1st Daily Cardiology Symposium
January 19, 2021Case-based review of common cardiometabolic practice
-
Residents’ Island: Abidi CVD Prevention Academy
January 12, 2021Multidisciplinary approach to CVD Prevention
-
A Polypill For the Prevention of CVD in Intermediate Risk Patients: Results of the International Polycap Study (TIPS-3 Trial)
December 2, 2020A quick review on the findings of TIPS-3 trial from AHA congress 2020
-
The role of Omega 3 and Vitamin D in the Primary Prevention of AF (VITAL-RHYTHM Trial)
December 2, 2020Dietary Supplements and AF
-
Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with T2DM and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED)
December 2, 2020The Important findings of SCORED trial from AHA 2020 congress in brief
-
High Dose Vs Standard Dose Influenza Vaccine in Patients with a High-Risk for Cardiovascular Disease (INVESTED)
December 2, 2020A quick review on the findings of INVESTED trial from AHA congress 2020
-
Effects of Evolocumab on Complex Coronary Disease Requiring Revascularization
November 30, 2020Evolocumab in the pipeline
-
Finerenone Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD Trial)
November 3, 2020Finerenone protecting kidneys
-
Ground-breaking research from ESC Congress 2020 (12)
September 16, 2020Part Twelve: Trial Review, EVAPORATE
-
-
-
-
Benefits of Targeting for a <70 mg/dL LDL Cholesterol During 5 Years After Ischemic Stroke
March 6, 2020The findings of TST study
-
Intensive LDL lowering beyond current recommendations for MACE prevention
February 12, 2020A meta-analysis of RCTs
-
-
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in T2DM
January 18, 2020The renal and cardiovascular protective effects of SGLT2 inhibitors
-
-
-
Inclisiran for patients with ASCVD and elevated LDL
December 2, 2019The findings of ORION-10 trial in ASCVD patients
-
Inclisiran in Heterozygous Familial Hypercholesterolemia (HeFH) and Elevated LDL
November 29, 2019The findings of ORION-9 trial about Inclisiran in HeFH
-
Optimal Medical Therapy vs. Revascularization in Chronic Coronary Syndrome
November 29, 2019The findings of ISCHEMIA trial
-
Triglyceride Lowering and Cardiovascular Risk Reduction
November 4, 2019A Systematic Review and Meta-Analysis of RCTs on TG lowering drugs
-
Guideline Made Easy
November 3, 2019Practical Guide for treatment of high blood cholesterol Part Three
-
-
Guideline Made Easy
October 3, 2019Practical Guide for treatment of high blood cholesterol Part Two
-
Ezetimibe for the prevention of heart disease and death
June 14, 2019The role of Ezetimibe in reducing CVD adverse outcomes
-
